Pfizer (PFE) Retained Earnings (2009 - 2026)

Pfizer (PFE) has reported Retained Earnings for 18 consecutive years, with $112.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings fell 4.7% year-over-year to $112.1 billion in Q2 2026; TTM through Jun 2026 was $112.1 billion, a 4.7% decrease from a year earlier, with the FY2025 full-year figure at $114.6 billion, down 1.81% from the prior year.
• Retained Earnings was $112.1 billion for Q2 2026 at Pfizer, down from $117.2 billion in the prior quarter.
• Over five years, Retained Earnings peaked at $131.1 billion in Q2 2023 and troughed at $111.2 billion in Q2 2022.
• A 5-year average of $119.4 billion and a median of $118.0 billion in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings rose 21.53% in 2022 and dropped 9.47% in 2024, its largest moves.
• Over 5 years, Retained Earnings stood at $125.7 billion in 2022, then declined by 5.81% to $118.4 billion in 2023, then declined by 1.38% to $116.7 billion in 2024, then declined by 1.81% to $114.6 billion in 2025, then declined by 2.2% to $112.1 billion in 2026.
• The last three Retained Earnings figures came in at $112.1 billion (Q2 2026), $117.2 billion (Q1 2026), and $114.6 billion (Q4 2025), per Business Quant data.